Stoke Therapeutics (STOK) – Analysts’ Weekly Ratings Changes

Stoke Therapeutics (NASDAQ: STOK) recently received a number of ratings updates from brokerages and research firms:

• 1/12/2026 – Stoke Therapeutics had its price target raised by analysts at Wedbush from $32.00 to $36.00. They now have an “outperform” rating on the stock.
• 1/5/2026 – Stoke Therapeutics had its price target raised by analysts at Canaccord Genuity Group Inc. from $28.00 to $36.00. They now have a “buy” rating on the stock.
• 1/5/2026 – Stoke Therapeutics was given a new $35.00 price target on by analysts at Loop Capital.
• 1/5/2026 – Stoke Therapeutics had its price target raised by analysts at Chardan Capital from $24.00 to $35.00. They now have a “buy” rating on the stock.
• 12/29/2025 – Stoke Therapeutics had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Stoke Therapeutics had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Stoke Therapeutics was given a new $50.00 price target on by analysts at UBS Group AG.
• 12/15/2025 – Stoke Therapeutics had its price target raised by analysts at HC Wainwright from $35.00 to $50.00. They now have a “buy” rating on the stock.
• 12/8/2025 – Stoke Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Stoke Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Stoke Therapeutics had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Stoke Therapeutics was upgraded by analysts at Chardan Capital to a “strong-buy” rating.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 13,430 shares of Stoke Therapeutics stock in a transaction on Monday, December 8th. The stock was sold at an average price of $32.27, for a total transaction of $433,386.10. Following the completion of the transaction, the director owned 49,124 shares in the company, valued at approximately $1,585,231.48. The trade was a 21.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Adrian R. Krainer sold 40,472 shares of the business’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $26.98, for a total value of $1,091,934.56. Following the completion of the sale, the director directly owned 364,246 shares in the company, valued at $9,827,357.08. This trade represents a 10.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 104,705 shares of company stock worth $3,070,910 over the last ninety days. Corporate insiders own 9.50% of the company’s stock.

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.